Managing Self-funded Risk

For the past twelve years, Sun Life has shared our data and insights with the self-funded marketplace to help employers and brokers understand trends around the highest-cost claims. While a lot has changed over the past decade, one thing has not: our commitment to providing you with actionable insights that can help you stay informed about conditions and medications most likely to result in a high-cost claim, and steps you can take to manage that risk as a self-funded employer

2024 Sun Life Stop-Loss Research report

Managing Self-funded Risk

2026 Future Forecast Video Series: Improving the Medical Moment

February 06, 2026

Hear from Jennifer Collier, President of Health and Risk Solutions and Dr. Miles Varn, Chief Medical Officer and Head of PinnacleCare on some top-of-mind topics as we enter the New Year.

Expert Cancer Review

August 15, 2025

Cancer is a top concern for self-funded employers. Watch our latest webinar on Sun Life's Expert Cancer Review (ECR) - a powerful new solution included in all stop-loss policies to support our self-funded clients and their employees facing cancer diagnoses.

High-Cost Claims Spotlight: The Value of Second Opinions - Musculoskeletal (MSK)

November 20, 2024

Research shows that up to half of elected orthopedic surgeries may be unnecessary. Learn how seeking a second medical opinion can lead to alternative outcomes, such as prehabilitation and rehabilitation, as well as emerging digital and regenerative therapies. These help in managing MSK issues and potentially avoiding or delaying the need for costly and risky surgical interventions.

High-Cost Claims Spotlight: The Value of Second Opinions – Cardiovascular Disease (CVD)

November 20, 2024

Learn how the value of second medical opinions, particularly for complex conditions like cardiovascular disease (CVD) can improve diagnostic accuracy, lead to more appropriate treatments, and ultimately drive better health outcomes and cost savings.

High-Cost Claims Spotlight: AI and Cancer Drug Development

October 09, 2024

Artificial intelligence (AI) and machine learning (ML) are being used to innovate drug development, particularly for cancer treatments. These advancements can make treatments faster, more cost-effective, and lead to more personalized and effective cancer therapies.

The Value of Second Opinions – Cancer

August 14, 2024

A second medical opinion can have a substantial influence on a patient’s well-being, treatment, and prognosis. Learn what you can do to help your employees manage these decisions more effectively, gain the confidence to make medical decisions, and how Health Navigator can help.

Mental health impacts of a breast cancer diagnosis

May 15, 2024

Breast cancer is one of the most common cancers in women in the U.S., and can take a severe emotional and mental toll on patients and their families. Sun Life's Bright Paper discusses the link between mental health and breast cancer, barriers to access treatment, recommendations, and more.

2024 Updates and 2023 Year in Review on Leave and Accommodations Webinar

February 28, 2024

Watch Marjory Robertson, AVP & Senior Counsel, Sun Life and Abigail O’Connell, Senior Counsel, Sun Life, for  a recap of 2023 legal and compliance developments related to leave and accommodation law. 

2023 Updates on Leave and Accommodation laws

September 20, 2023

Watch as Marjory Robertson, AVP & Senior Counsel, Sun Life U.S. and Abigail O’Connell, Senior Counsel, recap the latest 2023 leave and accommodation-related compliance developments. 

2023 High-cost claims and injectable drug trends analysis

May 17, 2023

For the past eleven years, Sun Life has shared our data and insights with the self-funded marketplace to help employers and brokers understand trends around the highest-cost claims.

Introduction to Gene Therapies (3rd edition)

February 06, 2023

Learn more about recently approved Hemgenix in the treatment of Hemophilia B, the gene therapy pipeline, the approval process, and what gene therapies are, in our second edition of the Introduction to Gene Therapies paper.